These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34904508)

  • 21. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
    Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
    Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
    Furuichi Y; Takeuchi H; Uojima H; Atsukawa M; Arai T; Arase Y; Kako M; Hidaka H; Itoi T
    J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):439-448. PubMed ID: 34953107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
    Ding Z; Wu H; Zeng Y; Kuang M; Yang W; Meng Z; Chen Y; Hao C; Zou S; Sun H; Liu C; Lin K; Shi G; Wang X; Fu X; Chen R; Chen Y; Liang R; Kano T; Pan H; Yang S; Fan J; Zhou J
    Hepatol Int; 2023 Feb; 17(1):180-189. PubMed ID: 36258065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
    Biolato M; Vitale F; Marrone G; Miele L; Grieco A
    Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
    Sakamaki A; Watanabe T; Abe S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
    Clin J Gastroenterol; 2017 Jun; 10(3):261-264. PubMed ID: 28324272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
    Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
    Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization.
    Fujita M; Abe K; Hayashi M; Okai K; Takahashi A; Ohira H
    Fukushima J Med Sci; 2017 Dec; 63(3):165-171. PubMed ID: 29142151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study.
    Kawaratani H; Tsuji Y; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Sato S; Takaya H; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Hepatol Res; 2020 Sep; 50(9):1101-1105. PubMed ID: 32558192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding events in lusutrombopag-treated thrombocytopenic patients.
    Giannini EG; Kano T; Ochiai T; Bentley R; Shrestha P; Afdhal N
    Eur J Clin Invest; 2021 Jun; 51(6):e13503. PubMed ID: 33523482
    [No Abstract]   [Full Text] [Related]  

  • 35. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
    Kaneko T; Takano Y; Ishibashi K
    Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance.
    Sasaki R; Shiino C; Imawari M; Bentley R; Cai B; Yoshida M; Afdhal N
    Hepatol Res; 2019 Oct; 49(10):1169-1181. PubMed ID: 31228221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study.
    Numata K; Tanaka K; Katsube T; Ochiai T; Fukuhara T; Kano T; Osaki Y; Izumi N; Imawari M
    Hepatol Res; 2020 Oct; 50(10):1141-1150. PubMed ID: 32609920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.